News
A NEW “game-changing” drug could stop the progression of Alzheimer’s disease, early trials suggest. Scientists say the ...
MedPage Today on MSN4d
Novel Anti-Amyloid Drug Aims to Outperform Current Standards
TORONTO -- An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta ...
Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...
Health and Me on MSN3d
New Drug Could Stop Alzheimer's In Its Tracks In Just 7 Months
A new drug cleared 91% of brain amyloid plaques in 7 months, showing faster results than current Alzheimer's treatments and advancing to Phase III trials in 2025.
In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months ...
A new Alzheimer’s drug has been hailed as a major breakthrough after clinical trials showed it could clear the harmful brain ...
Free Malaysia Today on MSN3d
New drug, new hope: Roche tests Trontinemab potential to delay or prevent Alzheimer’s
Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer’s disease ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s ...
Current health news covers Roche's Alzheimer's drug research, UnitedHealth's leadership hopes, Nordic Capital's ...
Swiss pharmaceutical giant Roche is set to explore the potential of its experimental drug, Trontinemab, in delaying or ...
GlobalData on MSN5d
Roche’s Alzheimer’s therapy shows continued benefit
Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.
Roche reveals new data on trontinemab and pTau217 testing, aiming to transform Alzheimer’s treatment and diagnosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback